Evaluation of the effect of L-carnitine administration on peritoneal membrane function in peritoneal dialysis patients.

Evaluation of the effect of L-carnitine administration on peritoneal membrane function in peritoneal dialysis patients. - Effect of L- carnitine administration in peritoneal dialysis patients

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000031514

Enrollment

Registered

2018-02-28

Start date

2018-02-28

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Secondary carnitine deficiency

Interventions

Levocarnitine 750mg/day Half a year No treatment

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1.Patients over the age of 20 years with end stage renal disease undergoing peritoneal dialysis 2.Patients able to provide written informed consent for study participation

Exclusion criteria

Exclusion criteria: 1.Patients under the age of 20 years old 2.Patients who are contraindicated in the package insert of Levocarnitine 3.Patients undergoing combination therapy with peritoneal dialysis and hemodialysis 4.Pregnant woman, or a woman who have possibility of pregnancy 5.Others not inadequate judged by a physician 6.Patients who do not obtain consent

Design outcomes

Primary

Measure	Time frame
Improvement of peritoneal membrane function by administration of L-carnitine	—

Secondary

Measure	Time frame
Residual renal function Cardiac function Erythropoietin resistant anemia Insulin resistance	—

Countries

Japan

Contacts

Public ContactSakuya Ito

Kurume University Division of Nephrology, Department on Medicine

itou_sakuya@med.kurume-u.ac.jp0942-31-7763

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026